Eloxx Pharmaceuticals, Inc.

OTCPK:ELOX Stock Report

Market Cap: US$3.0

Eloxx Pharmaceuticals Management

Management criteria checks 3/4

Eloxx Pharmaceuticals' CEO is Sumit Aggarwal, appointed in Apr 2021, has a tenure of 3.75 years. directly owns 5.15% of the company’s shares, worth $0.15. The average tenure of the management team and the board of directors is 3.8 years and 6.7 years respectively.

Key information

Sumit Aggarwal

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure3.8yrs
CEO ownership5.1%
Management average tenure3.8yrs
Board average tenure6.7yrs

Recent management updates

Recent updates

Eloxx says lead asset failed in mid-stage cystic fibrosis trial

Sep 14

Eloxx Pharmaceuticals GAAP EPS of -$0.12 in-line

Aug 15

Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

Sep 09
Is Eloxx Pharmaceuticals (NASDAQ:ELOX) Using Debt In A Risky Way?

Eloxx Pharmaceuticals EPS misses by $0.06

May 06

What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

Feb 17
What Kind Of Investors Own Most Of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX)?

Eloxx secures additional funding from CF Foundation for ELX-02 mid-stage study in cystic fibrosis

Jan 13

CEO Compensation Analysis

How has Sumit Aggarwal's remuneration changed compared to Eloxx Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$20m

Jun 30 2023n/an/a

-US$24m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$1mUS$575k

-US$36m

Sep 30 2022n/an/a

-US$42m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$70m

Dec 31 2021US$6mUS$408k

-US$67m

Compensation vs Market: Insufficient data to establish whether Sumit's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Sumit's compensation has been consistent with company performance over the past year.

CEO

Sumit Aggarwal (51 yo)

3.8yrs

Tenure

US$1,395,942

Compensation

Mr. Sumit Aggarwal, MBA serves as a Director at Eloxx Pharmaceuticals, Inc. since April 01, 2021. He is the President and Chief Executive Officer of Eloxx Pharmaceuticals, Inc. since April 01, 2021. He ser...

Leadership Team

NamePositionTenureCompensationOwnership
Sumit Aggarwal
President3.8yrsUS$1.40m5.15%
$ 0.2
Daniel Geffken
Interim CFO3.8yrsUS$63.96k0.038%
$ 0.001
Barbara Ryan
Investor Relations Officerno datano datano data
Ali Hariri
Chief Medical Officer3.2yrsno datano data

3.8yrs

Average Tenure

63yo

Average Age

Experienced Management: ELOX's management team is considered experienced (3.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Sumit Aggarwal
President3.8yrsUS$1.40m5.15%
$ 0.2
Steven Rubin
Independent Director7.1yrsUS$58.60k0.36%
$ 0.01
Alan Walts
Independent Director3.8yrsUS$61.10k0.39%
$ 0.01
Patrick Flume
Member of Medical Advisory Boardno datano datano data
Timor Baasov
Member of Scientific Advisory Boardno datano datano data
Noreen Henig
Member of Medical Advisory Boardno datano datano data
David Bedwell
Member of Scientific Advisory Board6.7yrsno datano data
Rachel Green
Member of Scientific Advisory Board6.7yrsno datano data
Sudhir Kumar
Member of Scientific Advisory Board6.7yrsno datano data
Lynne Maquat
Member of Scientific Advisory Board6.7yrsno datano data
Donald Vandevanter
Member of Medical Advisory Boardno datano datano data
Christiane De Boeck
Member of Medical Advisory Boardno datano datano data

6.7yrs

Average Tenure

61yo

Average Age

Experienced Board: ELOX's board of directors are considered experienced (6.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 09:47
End of Day Share Price 2025/01/07 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Eloxx Pharmaceuticals, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Arlinda LeeCanaccord Genuity
Andrew FeinH.C. Wainwright & Co.